Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib) May 20, 2008
In Japan, Glivec(R) is approved for the treatment of patients with Kit (CD117)-positive GIST. In the EU, Glivec(R) is also approved for the treatment of adult patients with newly diagnosed Ph+ acute lymphoblastic leukaemia (Ph+ ALL) in combination with chemotherapy and as a single agent for patients with relapsed or refractory Ph+ ALL. Glivec(R) is also approved for the treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) who are not... (PR Newswire)
Gleevec(R) Demonstrates Highest Five-Year Overall Survival Rate in History of Treatment for Patients With Chronic Myeloid Leukemia Dec 7, 2006
Gleevec tablets are also indicated for the treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP), relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), certain forms of myelodysplastic/myeloproliferative diseases (MDS/MPD), hypereosinophilic syndrome and/or chronic eosinophilic leukemia (HES/CEL) and aggressive systemic mastocytosis (ASM). Important Safety Information(1) Hematologic Disorders... (PR Newswire)
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options Oct 20, 2006
The solid tumor is dermatofibrosarcoma protuberans (DFSP), a type of tumor that begins as a hard lump found in the skin of the chest, abdomen or leg ... An approval for newly diagnosed patients is still under review by the FDA. In the European Union (EU), Gleevec was recently approved for treatment of certain patients with Ph+ ALL as well as for adult patients with a form of DFSP. The EU is also reviewing applications for approval of Gleevec as a treatment for the three other diseases MDS/MPD,... (PR Newswire)
Novartis completes submissions in US and Europe for Gleevec(R) as treatment for four rare types of cancer Apr 10, 2006
The diseases found to have Gleevec-sensitive pathways include the solid tumor dermatofibrosarcoma protuberans (DFSP), a type of tumor that begins as a hard lump found in the skin of the chest, abdomen or leg ... Novartis submitted the marketing applications in Europe and the United States for DFSP and MPD in 2005, and for SM and HES in 2006. (PR Newswire)
